Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Bcl-2 inhibitor ABBV-623

An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor ABBV-623 targets, binds to and inhibits the activity of Bcl-2. This restores caspase-mediated apoptosis in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis. Its expression is associated with increased drug resistance and tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BCL2 inhibitor ABBV-623
Code name:ABBV 623
ABBV-623
ABBV623
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search